Oppenheimer Raises PT On Endo Pharmaceuticals To $48

April 12, 2011 6:44 AM | 7 seconds read |

Oppenheimer has raised the price target on Endo Pharmaceuticals ENDP from $42 to $48 and maintains its Outperform rating.

Posted In: Price Target Analyst Ratings endo pharmaceuticals Health Care Oppenheimer Pharmaceuticals

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.